Nyxoah (NYXH) Current Deferred Revenue (2024 - 2025)
Nyxoah (NYXH) recorded quarterly Current Deferred Revenue of $1.0 million in Q4 2025, down 99.93% quarter-over-quarter from $1.6 billion in Q3 2025, and up 732.35% on a YoY basis from $125025.7 in Q4 2024.
Nyxoah (NYXH) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Nyxoah's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $1.0 million for Q4 2025.
- In Q4 2025, Current Deferred Revenue rose 732.35% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (up 732.35% YoY), while the FY2025 annual figure was $1.0 million, up 732.35% from the prior year.
- Current Deferred Revenue was $1.0 million for Q4 2025 at Nyxoah, down from $1.6 billion in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $1.6 billion in Q3 2025 to a low of $125025.7 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn |
| 10 | Nyxoah | 0.69 | 0.69 | 4.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.04 Mn |
| Sep 30, 2025 | 1.55 Bn |
| Mar 31, 2025 | 291,371.99 |
| Dec 31, 2024 | 125,025.66 |